MapLight Therapeutics, Inc. (NASDAQ:MPLT)
| Market Cap | $253.15M-57.5% |
| Revenue (ttm) | $0 |
| Net Income | -$252.02M-145.1% |
| EPS | -$5.44-119.4% |
| Shares Out | 42.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 357,935 |
| Open | $6.33 |
| Previous Close | $6.42 |
| Day's Range | $5.93 - $6.48 |
| 52-Week Range | $5.92 - $40.43 |
| Beta | 3.01 |
| Analysts | Buy |
| Price Target | $29.20(+391.58%) |
| Earnings Date | n/a |
About MPLT
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating MPLT in the last 3 months, one vote each. Issuer-paid research is not counted.
$MPLT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MPLT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MPLT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MPLT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MPLT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MPLT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MPLT
| IWMiShares Russell 2000 ETF | $2.08M |
| VXFVanguard Extended Market ETF | $1.58M |
| VTIVanguard Morningstar Total Stock Market ETF | $1.03M |
| IWOiShares Russell 2000 Growth ETF | $684.15K |
| VTWOVanguard Russell 2000 ETF | $580.81K |
| SCHASchwab U.S. Small-Cap ETF | $572.54K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MPLT’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-6.5 since Aug 27Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| ASD | Defiance Autism Impact ETF | 1.36% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.25% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.20% |
| IBRN | iShares Neuroscience and Healthcare ETF | 0.06% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.05% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
